Double-blind, Randomized, Multicenter, Placebo-Controlled Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for LDL-C Reduction in Pediatric Subjects 10 to 17 Years of Age With HeFH
Phase of Trial: Phase III
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms HAUSER-RCT
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 07 Apr 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 11 Feb 2016 Planned End Date changed from 1 Aug 2017 to 1 Mar 2018 as reported by ClinicalTrials.gov.